Regeneron Partners with TriNetX for 300M Patient Data
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...
SAN FRANCISCO, Calif., Oct. 7, 2025 — Verana Health announced the expansion of its MIPS Advisory Services, offering enhanced...
September 22, 2025 — Florida, USA — A recent real-world retrospective study of 359 adult patients with lower-risk myelodysplastic...
